| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 10/07/2004 | WO2004073728A3 Compositions comprising fetal hemoglobin and bacterial endotoxin and optionally additional fetal liver components |
| 10/07/2004 | WO2004067698A3 Helminth-derived antigens having capacity of providing protection against parasites |
| 10/07/2004 | WO2004067549A3 Peptides directed against antibodies, which cause cold-intolerance, and the use thereof |
| 10/07/2004 | WO2004067027A9 Osteogenic composition |
| 10/07/2004 | WO2004065613A3 Inducible small interfering rna (sirna) expression constructs for targeted gene silencing |
| 10/07/2004 | WO2004064855A8 Medicament and use thereof for tumor therapy |
| 10/07/2004 | WO2004064766A3 Method of treatment of conditions by administration of streptolysin o |
| 10/07/2004 | WO2004062681A8 Herbal compositions for prostate conditions |
| 10/07/2004 | WO2004062677A9 Bacteriophage for the treatment of bacterial biofilms |
| 10/07/2004 | WO2004060384A3 Pharmaceutical botulinum toxin compositions |
| 10/07/2004 | WO2004054607A3 Stable therapeutic proteins |
| 10/07/2004 | WO2004052228A3 Pharmacological vitreolysis |
| 10/07/2004 | WO2004048402B1 A hepatitis c virus codon optimized non-structural ns3/4a fusion gene |
| 10/07/2004 | WO2004043911A3 N-cycloalkylglycines as hiv protease inhibitors |
| 10/07/2004 | WO2004041176A3 The use of endoperoxides for the treatment of infections caused by flaviviridae, including hepatitis c, bovine viral diarrhea and classical swine fever virus |
| 10/07/2004 | WO2004040262A8 Compositions and methods for modifying toxic effects of proteinaceous compounds |
| 10/07/2004 | WO2004035754A3 Microencapsulation and sustained release of biologically active polypeptides |
| 10/07/2004 | WO2004028466A3 Ketoamide inhibitors in chronic nerve disease |
| 10/07/2004 | WO2004018629A3 Stars-a muscle-specification-binding protein |
| 10/07/2004 | WO2004015060A3 Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| 10/07/2004 | WO2004013303A3 Modified annexin proteins and methods for treating vaso-occlusive sickle-cell disease |
| 10/07/2004 | WO2004010934A3 Methods for the use of neurotoxin in the treatment of urologic disorders |
| 10/07/2004 | WO2004007674A3 Neuronal and retinal gene expression patterns |
| 10/07/2004 | WO2004004757A8 Treatment for eye disorder |
| 10/07/2004 | WO2004002418A3 Compositions and methods comprising protein activated receptor antagonists |
| 10/07/2004 | WO2003106648A3 Compositions and methods relating to breast specific genes and proteins |
| 10/07/2004 | WO2003101386A3 Kinase suppressor of ras inactivation for therapy of ras mediated tumorigenesis |
| 10/07/2004 | WO2003097662A8 Antisense modulation of apolipoprotein b expression |
| 10/07/2004 | WO2003092475A3 Diagnosis and treatment of glaucoma |
| 10/07/2004 | WO2003077848A3 Jagged 2 inhibitors for inducing apoptosis |
| 10/07/2004 | WO2003070981A8 Seequences specifically deleted mycobacterium tuberculosis genome and their use in diagnostics and as vaccines |
| 10/07/2004 | WO2003062420A8 Molecular libraries |
| 10/07/2004 | WO2003059942A3 Peptides and peptidomimetics having anti-proliferative activity and their use |
| 10/07/2004 | WO2003057725A3 Cell-permeable peptide inhibitors of the jnk signal transduction pathway |
| 10/07/2004 | WO2003018608A3 Process for purifying glycopeptide phosphonate derivatives |
| 10/07/2004 | WO2002100250A8 Wit 3.0, a novel gene to control soft tissue wound healing |
| 10/07/2004 | WO2002092000A3 Hbm variants that modulate bone mass and lipid levels |
| 10/07/2004 | WO2002088317A3 Fusion molecules and methods for treatment of immune diseases |
| 10/07/2004 | WO2002078636A3 Detection and treatment of colorectal cancer |
| 10/07/2004 | WO2002075278A3 Light-emitting fusion proteins and diagnostic and therapeutic methods therefor |
| 10/07/2004 | WO2002070647A3 Denaturat stable and/or protease resistant, chaperone-like oligomeric proteins, polynucleotides encoding same and their uses |
| 10/07/2004 | US20040198989 inhibitors of HIV protease for treating AIDS |
| 10/07/2004 | US20040198970 Maxp1 |
| 10/07/2004 | US20040198969 Compositions and methods for the diagnosis and treatment of tumor |
| 10/07/2004 | US20040198961 Fce fusion proteins for treatment of allergy and asthma |
| 10/07/2004 | US20040198949 Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
| 10/07/2004 | US20040198841 Pretreatment before chemotherapy; antiulcer agents for cancer therapy |
| 10/07/2004 | US20040198816 Administering mixture of anesthetic and adrenergic receptor antagonist; reverse with low dosage of adrenergic receptor antagonist; used for hair grafting |
| 10/07/2004 | US20040198715 prolonged serum half-life to permit treatment regimens of about once every 5-7 days or longer, while retaining antibacterial properties in vivo |
| 10/07/2004 | US20040198690 Methods and compositions for inhibiting the function of polynucleotide sequences |
| 10/07/2004 | US20040198689 Ribozyme sequences related to hiv resistance |
| 10/07/2004 | US20040198686 Administering resistin-like molecules alpha or beta |
| 10/07/2004 | US20040198683 Ex vivo and in vivo expression of the thrombomodulin gene for the treatment of cardiovascular and peripheral vascular diseases |
| 10/07/2004 | US20040198682 RNA interference mediated inhibition of placental growth factor gene expression using short interfering nucleic acid (siNA) |
| 10/07/2004 | US20040198681 Administering to human or animal at least one polypeptide or a nucleic acid sequence encoding said polypeptide; protein design or protein engineering in the production of polypeptides allowing delivery of food essential amino acids for milk production in cows, farm animal production or human food |
| 10/07/2004 | US20040198680 Dna bacteria; activate lymphocytes; nucleotide sequences; antigens; administering cytokines |
| 10/07/2004 | US20040198679 Use of inhibitors of expression or activity of p8/com1 for treating tumors |
| 10/07/2004 | US20040198674 Compositions for preventing hormone induced adverse effects |
| 10/07/2004 | US20040198666 Novel selective bradykinin (BK) B1 peptidic receptor antagonists and uses thereof |
| 10/07/2004 | US20040198665 caused by the cartilage growth inhibition resulting from mutations in the gene for fibroblast growth factor receptor 3; guanylyl cyclase B activator; gene therapy |
| 10/07/2004 | US20040198663 Method of treating cardiac ischemia by using erythropoietin |
| 10/07/2004 | US20040198662 a 15 to 22-residue polypeptide analog that forms an amphipathic alpha helix in the presence of lipids; anticholesterol agents; hypercholesterolemia, cardiovascular disorders, atherosclerosis, restenosis, hypertriglyceridemia, high density lipoprotein deficiency, metabolic disorders |
| 10/07/2004 | US20040198660 the TF antagonist is a factor VII polypeptide having reduced ability to catalyze factor X to factor Xa by being catalytically inactivated by a chloromethylketone inhibitor; anticoagulants, antiinflammatory agents; respiratory system disorders |
| 10/07/2004 | US20040198659 Therapy and diagnosis of conditions related to telomere length and/or telomerase activity |
| 10/07/2004 | US20040198658 Stanniocalcin polynucleotides, polypeptides and methods based thereon |
| 10/07/2004 | US20040198655 recombinant human ptx3 gene as a drug target and diagnostic marker for fertility drugs |
| 10/07/2004 | US20040198654 Glucagon-like peptide-1analogs |
| 10/07/2004 | US20040198653 administering somatostatin type-1,2 or 5 receptor oligopeptide agonists alone or in synergistic combination; antiproliferative agents |
| 10/07/2004 | US20040198652 using an antiendotoxin with an activated Protein C; continuous infusion, bolus, or intermittent infusion |
| 10/07/2004 | US20040198651 Secreted proteins |
| 10/07/2004 | US20040198650 Means for inhibiting proteolytical processing of parkin |
| 10/07/2004 | US20040198649 a VR4 peptide, a VR4 polypeptide modulator, a VR4 polynucleotide, or an antisense agent as analgesics or antiarthritic agents for bone and cartilage disorders; rheumatoid and osteoarthritis, osteoperosis; biodrugs |
| 10/07/2004 | US20040198648 Inhibition of alpha-2 hs glycoprotein (ahsg/fetuin) in obesity and insulin control of glucose homeostasis |
| 10/07/2004 | US20040198647 Compositions for treatment of hemorrhaging with activated factor VIIa in combination with fibrinogen and methods of using same |
| 10/07/2004 | US20040198645 Pharmaceutical compositions |
| 10/07/2004 | US20040198644 Integrin inhibitors for the treatment of eye diseases |
| 10/07/2004 | US20040198643 Antibacterial agent |
| 10/07/2004 | US20040198642 Glucagon-like peptide-2 activity intensifier and inhibitor mixture; gastrointestinal disorders; small- and irritable bowel syndrome, mucositis and Crohn's disease; appetite suppression; obesity |
| 10/07/2004 | US20040198639 Mixture with non-formaldehyde preservative; microbiocides; chemical resistance; drugs, medical equipment, cosmetics; antiaging, wrinkle resistance; skin disorders |
| 10/07/2004 | US20040198637 Protein arrays |
| 10/07/2004 | US20040198635 Reversal of viral-induced systemic shock and respiratory distress by blockade of the lymphotoxin beta pathway |
| 10/07/2004 | US20040197906 Oligonucleotides for controlling protein kinase a (PKA)gene expression for use in treatment of metabolic, developmental and cell proliferative disorders; gene expression inhibition |
| 10/07/2004 | US20040197901 Ancillary composition for the preparation of committed mature dentritic cells |
| 10/07/2004 | US20040197887 MIxtures of oxidoreductase enzymes, nicotinamido adenine dinucleotide coenzyme and vasodilators, complexed with phosphatides in solution, used for prophylaxis of hair loss |
| 10/07/2004 | US20040197876 Recombinant fusion proteins and the trimers thereof |
| 10/07/2004 | US20040197875 in which the B-domain is partially or completely deleted and may be replaced by a DNA linker segment; for use in human gene therapy |
| 10/07/2004 | US20040197874 Human cytokine polypeptide |
| 10/07/2004 | US20040197871 for diagnosing and treating inflammatory bowel disease using purified polypeptide; genetic engineering |
| 10/07/2004 | US20040197870 for drug screening anticancer/tumor agents using genetically engineered host cells |
| 10/07/2004 | US20040197867 promotes proteoglycan synthesis; used to induce bone formation in vivo; genetic engineering |
| 10/07/2004 | US20040197865 for detecting agonists of toll-like receptors/immune response modifier drugs genetic engineering |
| 10/07/2004 | US20040197864 Derivatives of magainin and methods of production thereof |
| 10/07/2004 | US20040197863 for use as anticancer/tumor agents using real-time polymerase chain reaction genetic engineering |
| 10/07/2004 | US20040197860 Polynucleotide constructs, pharmaceutical compositions and methods for targeted downregulation of angiogenesis and anticancer therapy |
| 10/07/2004 | US20040197853 largely reduced of antigenicity compared to native trichosanthin (TCS), while retaining anti-tumor, anti-virus, abortifacient, and ribosome-inactivating protein activities; for treating leukemia |
| 10/07/2004 | US20040197852 Method of preparing peptide fragment having cell death inhibitory activity |
| 10/07/2004 | US20040197827 Contacting with Ewing sarcoma protein and nuclear receptor; determining binding and changes in ligand-induced activity; use in diagnosis and treatment |
| 10/07/2004 | US20040197822 Nueregulin-beta isoforms associated with neuronal processes |
| 10/07/2004 | US20040197818 MinK-related genes, formation of potassium channels and association with cardiac arrhythmia |
| 10/07/2004 | US20040197809 Immunoglobulin fusion for prevention or treatment of viral infection; immunotherapy |